J Korean Ophthalmol Soc.  1986 Jun;27(3):321-325.

A Clinical Study on the Effect of Hibon-40(R): Riboflavin tetrabutyrate

• Joo CK
• Kim MS
• Kim JH

Abstract

Diseases caused by arteriosclerosis now occupy the first rank of the causes of death; they tend to increase further, and the countermeasure for adults' diseases is now noticed as one of big social problems. This study was devised to observe the effect of riboflavin tetrabutyrate on themetabolic changes in arteriosclerotic retinopathy, diabetic retinopathy, cataract and external eye diseases. After each case was treated three times daily for up to 13 weeks with riboflavin terabutyrate 120mg, we examined the visual acuity, retina changes, and cholesterol level at each visit. The results were as follows: 1. In arteriosclerotic retinopathy, visual improvement is noted in 44% of 18 cases and serum cholesterol level is decreased by 30.9mg/dl in average. 2. In diabetic retinopathy, visual improvement is noted in 37.5% of 16 cases and serum cholesterol level is decreased by 21.9mg/dl in average. 3. In cataract, visual improvement is noted in 8% of 12 cases and serum cholesterol level is reduced by 12.1mg/dl in average. 4. In external eye diseases, the symptoms and signs are much relieved.

MeSH Terms

Arteriosclerosis
Cataract
Cause of Death
Cholesterol
Diabetic Retinopathy
Eye Diseases
Retina
Riboflavin*
Social Problems
Visual Acuity
Cholesterol
Riboflavin